Role of activins in embryo implantation and diagnosis of ectopic pregnancy: a review

Bassem Refaat

Abstract
Embryo implantation is a major prerequisite for the successful establishment of pregnancy. Ectopic implantation outside the intrauterine cavity and the development of ectopic pregnancy (EP) is a major cause of maternal morbidity and occasionally mortality during the first trimester. EP may be induced by failure of tubal transport and/or increased tubal receptivity. Activins, their type II receptors and follistatin have been localised in the human endometrial and tubal epithelium and they are major regulators of endometrial and tubal physiology during the menstrual cycle. Pathological expression of activins and their binding protein, follistatin, was observed in tissue and serum samples collected from EP. Several studies with different designs investigated the diagnostic value of a single measurement of serum activin-A in the differentiation between normal intrauterine and failing early pregnancy and the results are controversial. Nevertheless, the diagnostic value of activins in EP, including the other activin isoforms (activin-B and –AB) and follistatin, merits further research. This review appraises the data to date researching the role of activins in the establishment of normal pregnancy and, pathogenesis and diagnosis of tubal EP.

Keywords: Activin, Fallopian tube, Endometrium, Implantation, Ectopic pregnancy, Early diagnosis

Background
The complex process of implantation and trophoblast invasion is crucial for the successful establishment of pregnancy [1-3]. Normally an embryo implants in the endometrium during the implantation window and uterine receptivity for implantation is maximal during this period [3]. Endometrial receptivity involves the expression of molecular factors that govern the feto-maternal dialogue and initiate decidualisation of the endometrial stroma [1,2]. Candidate molecules, including cytokines and growth factors, are secreted by endometrial and tubal epithelial cells and have been described as major regulators of blastocyst implantation [4].

Ectopic pregnancy (EP) is a form of abnormal pregnancy in which the fertilised ovum implants outside the intrauterine cavity and the ampullary region of the fallopian tube is the most common site of implantation [5,6]. EP represents 1-2% of all pregnancies in developed countries and haemorrhage from an EP due to tubal rupture remains the most common cause of maternal mortality in the first trimester of pregnancy in those countries [7-9]. Little is known about the reasons why embryos in some pregnancies implant within the fallopian tube whilst most implant eutopically within the endometrium of the uterus [4,10]. Ectopic implantation has long been attributed to failure of the tubal transport mechanism. Either/or the rhythmic smooth muscle contraction and ciliary beat activity are believed to fail thereby leading to an EP. An alternative explanation for EP would be an increase in tubal epithelial receptivity as a result of delay in the tubal transport and impaired endometrial receptivity with ectopic implantation occurring following failure of the normal biological interactions between endometrium, fallopian tube and embryo [4,10].

Quantitative measurement of human chorionic gonadotropin (hCG) in combination with transvaginal ultrasound is the currently accepted paradigm for clinical diagnosis and management of EP, with hCG monitoring being used to follow patients until complete resolution of the EP [7,8,11,12]. EP can be treated surgically by laparotomy and laparoscopy, medically by methotrexate (MTX) injection and occasionally by observation alone [8]. MTX is the most cost effective and has similar effect as laparoscopic
management on prospective fertility and recurrence of EP. However, it requires early detection of EP as it is only suitable in haemodynamically stable patients, with minimal or no symptoms, initial serum hCG ≤3000 IU/L, EP size <4 cm and absence of foetal cardiac activity [13-15].

It is believed that almost 50% of EP cases are initially misdiagnosed despite the use of high-resolution transvaginal sonography and sensitive assays for β-hCG [7,8,16,17].

The delay in the diagnosis of EP eliminates the option of conservative management, could lead to tubal rupture, maternal morbidity and/or mortality. Hence, there is a compelling need to develop new markers and algorithms that provide a more sensitive and specific tool for the diagnosis of EP [11,18,19].

Activins and their binding protein, follistatin, are abundantly expressed in the female reproductive tract and they have recently been proposed as potential sensitive and specific markers for the diagnosis of ectopic pregnancy by several research groups [20-22]. The current review summarises the physiological actions of activins and follistatin in the endometrium, fallopian tube, embryo implantation and their clinical value in the diagnosis of normal and abnormal early pregnancies.

Methods

‘Medline’ and ‘EMBASE’ were searched using the terms ‘endometrium’, ‘fallopian tube’, ‘implantation’, ‘early pregnancy’, ‘ectopic pregnancy’, ‘tubal pregnancy’, ‘early pregnancy loss’, ‘failing early pregnancy’, ‘receptivity’, ‘decidualization’, ‘implantation failure’ and ‘trophoblast’ in combination with ‘activin’ or ‘follistatin’ for studies published between 1987 and 2014. Publications in the past 6 years were mostly selected, but commonly referenced and important older publications were not excluded. The reference lists of articles identified by this search strategy were also searched and those judged as relevant were included. For a study to be included, it needed to be primarily focused on the expression of activins and their related molecules by the endometrial and tubal tissues, their roles in the establishment of normal and abnormal pregnancies and their serological diagnostic values in failing early pregnancies. Studies that were solely epidemiological in nature were excluded.

Structure, cell signalling and regulation of activins bioactivities

Activins are members of the transforming growth factor-β family and they were originally isolated from porcine follicular fluid in 1986. They were termed after their stimulatory effect on the secretion of follicle stimulating hormone from the pituitary gland. Activins were later found to be secreted by all organs of the female reproductive system where they function as paracrine and autocrine factors to regulate a variety of reproductive functions [21,23,24].

Activins are homodimers or heterodimers of two β-subunits (βA and βB), and the different dimerization of subunits by a disulphide bond gives rise to three mature proteins named activin-A (βA-βA), activin-B (βB-βB) and activin-AB (βA-βB) (Figure 1) [23]. The human activin βA-subunit and βB-subunit genes are located on chromosome7 locus7p14-p15 and chromosome 2cen-q13, respectively [25]. The mRNA of both subunits encodes a...
pre-proprotein, their mature regions illustrate about 70% sequence homology and both of them lack recognized glycosylation sites [26]. Activins mediate their actions by binding to a complex of transmembrane serine and threonine kinase receptors. These activin receptors are classified into type I and type II receptor groups, comprising the activin type IIA and type IIB receptors (ActRIIA and ActRIIB) [23]. Activins can bind their individual receptor type II when expressed alone, but fail to bind to type I receptor in the absence of type II receptor [27]. However, both type I and II receptors are necessary to generate a high-affinity complex with the ligand, as well as for signalling (Figure 2) [28].

The coordinated synthesis of follistatin with activin is the main regulator of the local bioactivity of activin since binding of activin to follistatin is almost irreversible [23]. The activin-follistatin complex generally consists of one activin dimer and two follistatin molecules [29]. In general, activin-A, -AB, and -B bind to follistatin with similar affinity (Figure 3) [30].

Both activin subunits, activin type II receptors and follistatin were previously localised within the human fallopian tube [23,31], endometrium [32-34] and placental [35] tissues suggesting a role for these proteins in the regulation the physiological functions of these tissues. Therefore these proteins have been proposed as potential sensitive and specific markers to monitor the progress and outcome of pregnancy [36,37].

Roles of activins in normal early pregnancy events
Activins are potential factors for maternal–embryo interactions, due to their roles in regulating cell proliferation, differentiation and apoptosis, and their abundant expression and actions in remodelling tissues, embryogenesis and organogenesis in a variety of species [34,38].

Activins in tubal physiology
Fertilisation and pre-implantation embryo development occur in the fallopian tube following ovulation and, the tubal epithelium is biologically active providing secretions to support these processes [23,38]. The fertilised ovum travels through the fallopian tube under the control of tubal ciliary beat frequency and tubal smooth muscle contraction to reach to the intrauterine cavity for implantation within 48–72 h after fertilisation [39]. Impaired tubal transportation and secretory functions can occur after external or internal inflammation, leading to tubal damage, ectopic pregnancy and infertility [40].

Early reports on the expression of activin subunits in the fallopian tube were generated from different animal species. Originally, only βA-subunit expression was detected at the protein and gene levels in rat [41] and bovine [42] tubal tissues. Follistatin expression was not included in either study [41,42]. Consistently, the expression of activins and follistatin by the human endosalpinx in pre- and postmenopausal women has been demonstrated [23,31]. In all tissues studied, the βA- and βB-subunits were co-expressed with their type II receptors and binding protein, suggesting that the activin dimer has a local paracrine or autocrine role within the tube [23,31].

Another study has later reported that the expression of both activin subunits mRNA and protein vary in a cycle-dependent manner in the oviduct of non-pregnant cycling mice [34]. The predominant source of activin β-subunits during the estrous cycle and pre-implantation phase were the epithelial cells lining the oviduct and endometrium [34]. A similar pattern of expression by the tubal epithelium during the menstrual cycle has also been reported in human fallopian tube and the expression of activin βA- and βB-subunits, activin type II receptors, and follistatin was highest in the luteal phase at the gene and protein levels. These results suggest that

---

**Figure 2** The signalling mechanism of activin. (1) Activin dimer binds to the activin type II receptors, (2) which in turn recruit and (3) phosphorylate the type I receptors. (4) The activin type I receptors transduce the activin signal to the nucleus.
activins and their related molecules play a role in tubal physiology and early embryonic development [38].

The mouse and human oocyte is capable of receiving an activin signal produced by surrounding cumulus cells, but not of transmitting one [43]. This is further supported by the findings that early mouse and human embryos, from the four-cell stage to the morula stage, are unable to synthesise activins as no mRNA for these proteins has been identified at these stages of development [41,44]. However, the expression of these molecules increased noticeably at the blastocyst stage, suggesting that the expression of the βA-subunit, activin type I receptor and follistatin is dependent on embryonic developmental stage and activation of the embryonic genome in mouse and human [44]. Therefore it has been postulated that activins, which bind to the activin type I and type II receptors on the oocyte and preimplantation embryo, may be derived from the surrounding tissue such as the tubal epithelium [34,44].

At the present time, there is no evidence about a role for activins in the regulation of tubal ciliary beat frequency and smooth muscle contraction [6,38]. However, several studies have shown that activin-A induces the production of nitric oxide, a potent inhibitor of tubal peristalsis, in a concentration-dependent manner in a variety of tissues and cells [6,38]. However, it has shown that activin-A decreased the expression of oxytocin and HoxA-10 mRNA by human myometrial cells in vitro and it decreased oxytocin and thromboxaneA2 induced accumulation of intracellular Ca^{2+} [48]. Therefore, activin-A could have a relaxing effect on human fallopian tube smooth muscle by stimulating the production of nitric oxide and/or by decreasing accumulation of intracellular Ca^{2+} [6].

**Activins in endometrial physiology**

The endometrium performs morphological and secretory adjustments during the menstrual cycle to form a receptive soil for the arriving blastocyst in the late luteal phase [1,2,4]. These alterations include the appearance of pinopodes in the epithelial layer, decidualization of the endometrial stroma and vascular proliferation, which are absolute requirements for successful implantation and establishment of communications with the embryo [1,2,4]. These modifications occur under the regulation of ovarian hormones to provide a microenvironment rich in cell adhesion molecules, cytokines, chemokines and growth factors [1,4,49,50].

Activins have been described as important regulators of decidualisation and endometrial receptivity following the identification of their expression in the endometrium of several species at the gene and protein levels. Activin subunits are expressed in the endometrium luminal and glandular epithelium of several species including human [21,34,51,52]. The co-expression of activin subunits, receptors and binding protein indicates that endometrial epithelial and stromal cells are capable of generating and responding to activin, and that there is a tight local regulation of activin actions within the endometrium [53].

The expression of activin and its related molecules varies during the menstrual cycle in the human endometrium as the uterus remodels and differentiates to form the decidua [54,55]. Activin βA- and βB-subunits mRNA and protein are expressed by glandular and surface epithelium in non-pregnant endometrium [55] and, dimeric activin-A is present in uterine fluid [53] and menstrual blood [56] of cycling women. The expression of activin subunits is localised in the cytoplasm of endometrial epithelium and it significantly increases in
the luminal and glandular epithelial cells during the secretory phase and remains relatively constant over the rest of the cycle [53,55]. Furthermore, activin-A measured in endometrial washes collected from cycling women correlated significantly with menstrual cycle days and the thickness of endometrium [53].

A similar pattern of expression has also been observed in the stromal cells during the cycle and the expression was strongest in the late secretory phase where decidualisation and embryo implantation occur [54,55]. Further evidence for the up-regulation of activin subunits synthesis with decidualisation was obtained from studies where the endometrium was extensively decidualised by intrauterine delivery of progestin [57] and in gene array studies examining decidualisation-related genes [58]. Newly decidualised cells are the main source of maternally derived activin-A during pregnancy to facilitate the spread of decidualisation throughout the endometrium by promoting the decidualisation of neighbouring cells [32-34,57,59].

During pregnancy, the placenta is a major source of serum activin-A, which increases as the pregnancy progresses [21,24,60,61]. However, the expression of activins by the cytotrophoblast is low during early pregnancy suggesting that trophoblast invasion is induced by maternally derived activins [32]. Activin-A regulates trophoblastic cell adhesive properties by modulating the expression of E- and N-cadherin [62,63] and integrins [35]. activin-A also promotes invasion of first-trimester cytotrophoblasts until 10 weeks gestation by increasing the expression of matrix metalloproteinases-2, 7 and 9 and its actions are inhibited by follistatin [33].

Activins in the pathogenesis and diagnosis of EP

Studies on the expression pattern of activins, their type II receptors and follistatin by fallopian tubes bearing an ectopic pregnancy have shown a significant increase in βA-subunit, type IIA and IIB receptors and follistatin compared to normal control [6,10]. Coherently, an increase in the expression of those molecules was also observed in tubal samples collected from patients with EP and who were positive for Chlamydia trachomatis antibodies when compared to tubal samples collected from EP patients and who had negative reaction for the antibodies [5]. Nevertheless, a recent study did not detect significant difference in the expression pattern of these molecules between implantation and remote sites collected from archived tubal pregnancy specimens. Hence, it has been postulated that the pathologic expression of activins and their related molecules by the tubal epithelium may play an important role in the pathogenesis of EP but not in the determination of implantation site [10].

Serum levels of activin-A and follistatin increase significantly throughout pregnancy and several studies have proposed a feto-placental origin for these proteins. Serum levels of activin-A also decrease in the presence of non-viable trophoblast [21,64,65]. Consequently, activin-A has been investigated as a potential marker for the diagnosis and differentiation between normal intrauterine pregnancy (IUP), miscarriage and ectopic pregnancy [37]. However, the reported results about the diagnostic value of activin-A are still debatable (Table 1).

The initial study by Florio et al. (2007) [36] demonstrated that a single measurement of serum activin-A

| Research group | Publication year | Study design | Number of patients | First trimester gestational age | Cut-off value | AUC | Sensitivity | Specificity | Reference number |
|----------------|------------------|--------------|--------------------|--------------------------------|---------------|-----|-------------|-------------|------------------|
| Florio et al.  | 2007             | Prospective observational | 536 PUL            | Not reported                   | 370 pg/mL     | 1.00| 100%        | 99.6%       | [36]             |
| Kirk et al.    | 2009             | Prospective observational | 141 PUL            | Not reported                   | 370 pg/mL     | 0.51| 93%         | 13%         | [71]             |
| Florio et al.  | 2011             | Retrospective case-control | 30 EP & 30 IUP     | Between 6 to 8 weeks           | 430 pg/mL     | 0.99| 96.7%       | 100%        | [66]             |
| Rausch et al.  | 2011             | Retrospective case-control | 100 EP & 100 IUP   | EP 45.15 ± 18.95; IUP 48.8 ± 18.34 days | 376.15 pg/mL | 0.78| 80%         | 72%         | [22]             |
| Warrick et al. | 2012             | Retrospective cohort study | 89 EP, 100 IUP & 100 AB | Median EP 5 weeks (1–10 weeks); A8 and IUP 7 weeks (1–10 weeks) | < 260 pg/mL | 0.62| 59.6%       | 61%         | [72]             |
| Roghaei et al. | 2012             | Prospective case-control | 100 EP & 100 IUP   | EP 6.32 ± 1.03 weeks; IUP 6.85 ± 1.82 weeks | 504 pg/mL     | 0.981| 97%        | 93.5%       | [69]             |
| Daponte et al. | 2013             | Prospective case-control | 30 EP, 30 AB & 33 IUP | Between 6 to 8 weeks           | 504 pg/mL     | 0.979| 87.9%       | 100%        | [67]             |

(AUC = area under the curve by receiver operator characteristics).
provided a highly sensitive and specific marker in 536 patients with pregnancy of unknown location (PUL) to discriminate between viable normal IUP, miscarriage and EP with a sensitivity of 100% and specificity of 99.6% at a cut-off value of 370 pg/mL. Later, the same research team has reported that serum concentrations of activin-A were significantly lower in 30 patients diagnosed with tubal EP when compared to control and, a sensitivity of 96.7% and a specificity of 100% for the diagnosis of EP was achieved at the cut-off level of 0.43 ng/mL [66]. These results have also been confirmed by other research groups in the following years but with a different cut-off value of 504 pg/mL that achieved a sensitivity of 97% and specificity of 93.5% [22,67-70]. Additionally, Daponte et al. (2013) [67] also measured the sensitivity and specificity of follistatin in the diagnosis of EP. Their results have shown that both serum follistatin and activin-A/follistatin ratio had lower performance compared to serum activin-A in the diagnosis of EP.

Oppositely, another two studies reported that a single measurement of serum activin-A was neither sensitive nor specific for the diagnosis of early pregnancy failure including EP compared to β-hCG [71,72]. Their results demonstrated that serum activin-A levels gave an area under the curve (AUC) of 0.61 for failing PUL, 0.64 for IUP and 0.51 for EP, and the model based on serum hCG levels gave an AUC of 0.95 for failing PUL, 0.97 for IUP and 0.67 for EP [71].

The inconsistencies in the reported cut-off values and the results of the different studies could be due to variability in trophoblastic activities and inadequate decidualisation during ectopic implantation [67]. It has also been suggested that some trophoblastic cells may behave as failing pregnancy during EP while other EPs could have more activity and behave more like IUPs [71], which could provide a possible explanation for the reported variations in serum levels of activin-A in women with EP [67].

Another explanation for the aforementioned variations in the results of activin-A could be related to the gestational age of the enrolled participants in the different studies. The increase in serum activin-A and follistatin during normal pregnancy starts at week 6 and reaches its peak at week 38 of pregnancy. The original study by Florio et al. (2007) [36], included patients in the first trimester but the authors have not reported the gestational age for control, EP and miscarriage groups. In the following study by Rausch et al. (2011), the mean gestational age for EP and IUP was 45.15 ± 18.95 and 48.8 ± 18.34 days, respectively [22]. The most recent studies that have reported a diagnostic value for serum activin-A included only patients between 6 to 8 [67] and 5 to 6 weeks gestational age [70].

Alternatively, the two studies that showed no value for serum activin-A in the diagnosis of EP the gestational age for each group was not reported by Kirk et al. (2009) [71] and Warrick et al. (2012) [72] applied a retrospective design that included pregnant females with ≤10 weeks gestation. The ectopic pregnancy group in study reported by Warrick et al. (2012) [72] had a median of 5 weeks (range 1–10 weeks) gestation compared to 7 weeks (range 1–10 weeks) for both IUP and miscarriage. Therefore, future studies should categorise the patients with failing early pregnancy according to gestational age (e.g. ≤ and >6 weeks) and to compare the results with those obtained from gestational aged matched controls.

The biological activities of activins are tightly regulated by follistatin as the binding of activin to follistatin is almost irreversible [23]. Serum activin is commonly bound with the long form follistatin (FS-315) [29], while the short form (FS-288) has high affinity for cell membrane activins [73]. The currently available ELISA kits for the detection of activin-A and follistatin cannot distinguish between the free and bound forms of both proteins. Furthermore, the follistatin kit measures both the long and short forms. Therefore, the reported results from the different studies are shown at the level of total activin-A and follistatin and the development of ELISA kits that measure the free form of both proteins would expose more precisely their values in the diagnosis of early pregnancy failure.

Additionally, the majority of studies that demonstrated the localisation of activins in the endometrium and placental tissues investigated the expression pattern of the βA- and βB-subunits and not the mature dimeric proteins. Hence, it could be postulated that the endometrium and trophoblast are capable of synthesising the different activin mature dimers (activin-A, –B and -AB). Moreover, generated results from gene knock-out studies have shown that each activin subunit has distinct functions and these sub-units do not functionally overlap in all settings in vivo [74,75]. Hence, the inclusion of the other activin mature dimeric proteins (e.g. activin-B and –AB) could add to the performance of serum activin-A in the diagnosis of abnormal early pregnancy.

**Conclusions**

Ectopic pregnancy is worldwide health problem and it is the leading cause of maternal morbidity and/or mortality during the first trimester. Early diagnosis of EP would allow more conservative treatment approaches and preservation of prospective fertility. However, the currently used diagnostic modalities lack accuracy, reproducibility and simplicity in the prediction of EP.

Activins and their related proteins play an important role in the regulation of endometrial receptivity, trophoblast activity and embryo implantation. Pathological expression of these candidate proteins have been associated with abnormal implantation and failing early pregnancy at
the tissue and serum levels. Although, the diagnostic value of a single measurement of serum activin-A in differentiating abnormalities from normal pregnancy is controversial, it merits further research.

Future studies should classify the patients according to the gestational age and to include other activin mature dimer proteins. It could also be worthwhile to combine serum activins with other serum biomarkers (e.g., inhibins, vascular endothelial growth factor) for early and accurate diagnosis of EP. Additionally, the development of ELISA kits that measure the free form of activins could increase their diagnostic performances. Further studies are needed to develop biomarkers and diagnostic modalities for the early diagnosis of EP and prevention of its associated maternal complications.

Competing interests
The author declares that he has no competing interests.

Acknowledgements
The author would like to thank the Institute of Scientific Research and Revival of Islamic Heritage at Umm Al-Qura University (project # 43300009) for the financial support.

Received: 20 September 2014 Accepted: 17 November 2014 Published: 25 November 2014

References
1. Singh M, Chaudhry P, Asselin E. Bridging endometrial receptivity and implantation: network of hormones, cytokines, and growth factors. J Endocrinol 2011, 210:5–14.
2. Dimitriadis E, White CA, Jones RL, Salamonsen LA. Cytokines, chemokines and growth factors in endometrium related to implantation. Hum Reprod Update 2005, 11(5):539–630.
3. Coughlan C, Ledger W, Wang Q, Liu F, Demiroi A, Gurban T, Cattin R, Ong K, Sallam H, Li TC. Recurrent implantation failure: definition and management. Reprod Biomed Online 2014, 28:14–38.
4. Jia-Rong Z, Shuang-Or L, Xiao-Ping W. Eutopic or ectopic pregnancy: a competition between signals derived from the endometrium and the fallopian tube for blastocyst implantation. Placenta 2009, 30(8):735–839.
5. Refaat B, Al-Aenzi M, Geary J, Eley A, Ledger W. Role of activins and inducible nitric oxide in the pathogenesis of ectopic pregnancy in women with or without Chlamydia trachomatis infection. Clin Vaccine Immunol 2009, 16:1493–1503.
6. Refaat B, Amer S, Ola B, Chapman N, Ledger W. The expression of activin-betaA- and -betaB-subunits, follistatin, and activin type II receptors in fallopian tubes bearing an ectopic pregnancy. J Clin Endocrinol Metab 2008, 93:299–299.
7. Jukic D, Wilkinson H. Diagnosis and management of ectopic pregnancy. BMJ 2011, 342:d3397.
8. Sivalingham VN, Duncan WC, Kirk E, Shephard LA. Home AW. Diagnosis and management of ectopic pregnancy. J Fam Plan Reprod Health Care 2011, 37:231–240.
9. Khan KS, Wodyla D, Say L, Guinepouly AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367:1066–1074.
10. Refaat B, Simpson H, Britton E, Biswas J, Wells M, Aplin JD, Ledger W. Why does the fallopian tube fail in ectopic pregnancy? The role of activins, inducible nitric oxide synthase, and MUC5C in ectopic implantation. Fertil Steril 2012, 97:1115–1123.
11. Kao LY, Scheinfeld MH, Chernyak V, Rosenblit AM, Oh S, Dym RJ Beyond ultrasound. CT and MRI of ectopic pregnancy. AJR Am J Roentgenol 2014, 202:904–911.
12. Kirk E, Bottomley C, Bourne T. Diagnosing ectopic pregnancy and current concepts in the management of pregnancy of unknown location. Hum Reprod Update 2014, 20:250–261.
13. Hajenius PJ, Mol F, Mol BW, Bosuyt PM, Arnkum WM, van der Veen F. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2007, 1:CD003324.
14. Lipscumb GH. Medical therapy for ectopic pregnancy. Semin Reprod Med 2007, 25:95–98.
15. Bachman EA, Barnhart K. Medical management of ectopic pregnancy: a comparison of regimens. Clin Obstet Gynecol 2012, 55:440–447.
16. Dillon KE, Sioulas VO, Sammel MD, Chung K, Takacs P, Shaukin A, Barnhart KT. How and when human chorionic gonadotropin curves in women with an ectopic pregnancy mimic other outcomes: differences by race and ethnicity. Fertil Steril 2012, 98:911–916.
17. Morse CB, Sammel MD, Shaukin A, Allen-Taylor L, Oberfoell NL, Takacs P, Chung K, Barnhart KT. Performance of human chorionic gonadotropin curves in women at risk for ectopic pregnancy: exceptions to the rules. Fertil Steril 2012, 97:101–106.e2.
18. Cartwright J, Duncan WC, Critchley HO, Home AW. Serum biomarkers of tubal ectopic pregnancy: current candidates and future possibilities. Reproduction 2009, 138:9–22.
19. Caldar FR, Fettback RB, Pereda PP, Zugaib M. Serum markers in the diagnosis of tubal pregnancy. Clinics (Sao Paulo) 2008, 63:701–708.
20. Barnhart K, Speicher DW. Molecular diagnosis of ectopic pregnancy. Expert Rev Mol Diagn 2011, 11:759–762.
21. Floro P, Luisi S, Ciampella P, Severi FM, Bocchi C, Pietragna F. Inhibins and activins in pregnancy. Mol Cell Endocrinol 2004, 225:93–100.
22. Rausch ME, Sammel MD, Takacs P, Chung K, Shaukin A, Barnhart KT. Development of a multiple marker test for ectopic pregnancy. Obstet Gynecol 2011, 117:573–582.
23. Refaat BA, Bahathiq AO, Sockanathan S, Stewart RL, Wells M, Ledger WL. Production and localization of activins and activin type IA and IB receptors by the human endosalpinx. Reproduction 2004, 128:249–255.
24. Schneider-Kolisky M, D’Antona D, Evans LW, Taylor N, O’Connor A, Groome NP, de Ketser D, Wallace EM. Maternal serum total activin A and follistatin in pregnancy and parturition. BIOC 2000, 107:995–1000.
25. Barton DE, Yang-Feng TL, Mason AJ, Seeburg PH, Francke U. Mapping of genes for inhibin subunits alpha, beta A, and beta B on human and mouse chromosomes and studies of jid mice. Genomics 1989, 5:91–99.
26. Mason AJ, Hayflick JS, Ling N, Esc H, Ueno N, Ying SY, Guirillon M, Niall H, Seeburg PH. Complementary DNA sequences of ovarian follicular fluid inhibit show precursor structure and homology with transforming growth factor-beta. Nature 1985, 318:659–663.
27. Ebner R, Chen RH, Lawler S, Zioncheck T, Denyck R. Determination of type I receptor specificity by the type II receptors for TGF-beta or activin. Science 1993, 262:900–902.
28. Wrana JL, Tran H, Attisano L, Arora K, Childs SR, O’Connor MB. Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex. Mol Cell Biol 1994, 14:944–950.
29. Schneyer AL, Hall HA, Lambert-Messerlian G, Wang QF, Sluss P, Crowley NP, de Kretser D, Wallace EM. Complex expression patterns support potential roles for maternally expressed activin receptors by the human endosalpinx. Mol Endocrinol 2009, 23:1054–1066.
30. Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS. The structure of the follistatin/activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 2005, 9:535–543.
31. Bahathiq AO, Stewart RL, Wells M, Moore HD, Pacey AA, Ledger WL. Production of activins by the human endosalpinx. J Clin Endocrinol Metab 2002, 87:5283–5289.
32. Jones RL, Findlay JK, Fimworth PG, Robertson DM, Wallace E, Salamonsen LA. Activin A and inhibin A differentially regulate human uterine matrix metalloproteinases; potential interactions during decidualization and trophoblast invasion. Endocrinology 2006, 147:724–732.
33. Jones RL, Findlay JK, Salamonsen LA. The role of activins during decidualisation of human endometrium. Aust N Z J Obstet Gynaecol 2006, 46:245–249.
34. Jones RL, Kaitu’U-Leiho TJ, Nie G, Sanchez-Partida LG, Findlay JK, Salamonsen LA. Complex expression patterns support potential roles for maternally derived activins in the establishment of pregnancy in mouse. Reproduction 2006, 132:799–810.
35. Stoilos CJ, Salamonsen LA, Hannan NJ, O’Connor AE, Rombouts L, Dimitriadis E. Activin A regulates trophoblast cell adhesive properties: implications for implantation failure in women with endometriosis-associated infertility. Hum Reprod 2010, 25:1767–1774.
36. Florio P, Severi FM, Bocchi C, Luisi S, Mazzini M, Danero S, Torricelli M, Petraglia F: Single serum activin a testing to predict ectopic pregnancy. J Clin Endocrinol Metab 2007, 92:1748–1753.

37. Prakash A, Laird S, Tuckerman E, Li TC, Ledger WL: Inhibin A and activin A may be used to predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril 2005, 83:1758–1763.

38. Reis FM, Ledger W: The expression of activins, their type II receptors and follistatin in human Fallopian tube during the menstrual cycle and in pseudo-pregnancy. Hum Reprod 2011, 26:3346–3354.

39. Lyons RA, Saridogan E, Dahanakshel O: The effect of ovarian follicular fluid and peritoneal fluid on Fallopian tube ciliary beat frequency. Hum Reprod 2006, 21:52–56.

40. Kriebi J, Fahey JO: Ectopic pregnancy. J Midwifery Womens Health 2006, 51:431–439.

41. Lu RZ, Matsuyama S, Nishihara M, Takahashi M: Expression of inhibin/activin subunits and their receptors and binding proteins in human preimplantation embryos. Biol Reprod 1993, 49:1163–1169.

42. Gandolfi F, Modina S, Brevini TA, Passoni L, Petraglia F, Lauria A: The paracrinology of tubal ectopic pregnancy. Expert Rev Mol Med 2009, 11:e7.

43. Sisidi V, Fujitava T, Leykin L, Isaacson K, Toth T, Schnyer AL: Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin’s paracrine signaling from granulosa cells to oocytes. Biol Reprod 1998, 59:807–812.

44. He ZY, Liu HC, Mele CA, Barant L, Veccle LL, Davis O, Rosenwaks Z: Expression of inhibin/activin subunits and their receptors and binding proteins in human preimplantation embryos. J Assist Reprod Genet 1999, 16:73–80.

45. Nusing RM, Barsig J: Inflammatory potency of activin A. Effect on prostanooid and nitric oxide formation. Adv Exp Med Biol 1997, 407:243–248.

46. Lagadec P, Raynal S, Lieuxbaux B, Otier N, Armouled L, Saint-Giregio V, Lawrence DA, Jeannin JF: Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta 1 in tumor cells. Implications for tumor development. Am J Pathol 1999, 154:1867–1876.

47. Nusing RM, Barsig J: Induction of prostaglandin, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A. Br J Pharmacol 1999, 127:919–926.

48. Ciarmela P, Water F, Vale W: Activin A in myometrium: characterization of the actions on myometrial cells. Endocrinology 2008, 149:2506–2516.

49. Home AW, Critchley HO: Mechanisms of disease: the endocrinology of ectopic pregnancy. Expert Rev Mol Med 2012, 14:e7.

50. Shaw JL, Home AW: The paracrinology of tubal ectopic pregnancy. Mol Cell Endocrinol 2012, 352:216–222.

51. Sugawara K, Kizaki K, Herath CB, Hasegawa Y, Hashizume K: Transforming growth factor beta family expression at the bovine feto-maternal interface. Reprod Biol Endocrinol 2010, 8:21.

52. Zhang H, Nagakura K, Imakawa K, Nambo Y, Watanabe G, Taya K, Weng Q: Expression of inhibin/activin subunits in the equine uterine during the early pregnancy. Reprod Domest Anim 2013, 48:423–428.

53. Florio P, Severi FM, Luisi S, Ciarmela P, Calonaci G, Cobellis L, Petraglia F: Endometrial expression and secretion of activin A, but not follistatin, increase in the secretory phase of the menstrual cycle. J Soc Gynecol Invest 2003, 10:237–243.

54. Mylonas I, Makovitzky J, Hoenig A, Richter DU, Vogl J, Schulze S, Jeschke U, Biese V, Friese K: Inhibin/activin subunits beta-A (β2) and beta-B (β2) are differentially localized in normal, hyperplastic and malignant human endometrial tissue. Acta Histochem 2006, 108:1-11.

55. Mylonas I, Jeschke U, West I, Hoenig A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupca MS, Friese K: Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol 2004, 122:461–471.

56. Reis FM, Nascimento LL, Tigkou A, Ferreira MC, Luisi S, Petraglia F: Activin A and follistatin in menstrual blood: low concentrations in women with dysfunctional uterine bleeding. Reprod Sci 2007, 14:385–389.

57. Jones RL, Salamonsen LA, Zhao YC, Ether JF, Drummond AE, Findlay JK: Expression of activin receptors, follistatin and betaglycan by human endometrial stromal cells; consistent with a role for activins during decidualization. Mol Hum Reprod 2002, 8:363–374.